A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2019
Price : $35 *
At a glance
- Drugs Ianalumab (Primary)
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 25 Oct 2019 Status has been changed to discontinued.
- 13 Jul 2018 Planned End Date changed from 1 Aug 2016 to 1 Oct 2018.
- 13 Jul 2018 Status changed to active, no longer recruiting.